Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults

Conditions: Human Immunodeficiency Virus Interventions: Biological: Ad26.Mos4.HIV [Arm 1]; Biological: Ad26.Mos4.HIV [Arm 2]; Biological: CH505 TF chTrimer+ALFQ [Arm 1]; Biological: CH505 TF chTrimer+ALFQ [Arm 2]; Biological: ALFQ [Arm 1]; Biological: ALFQ [Arm 2] Sponsors: U.S. Army Medical Research and Development Command; Janssen Vaccines& Prevention B.V.; Henry M. Jackson Foundation for the Advancement of Military Medicine; Duke University; Walter Reed Army Institute of Research (WRAIR); National Institute of Allergy and Infectious Diseases (NIAID); Makerere University Walter Reed Project Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials